← Back to all signals
RESEARCH PAPER ANALYSIS

A case of acute hemolytic transfusion reaction caused by anti-CD99.

Case report of a 74-year-old woman (with a history of Parkinson's disease) who experienced an acute hemolytic transfusion reaction caused by anti‑CD99 alloantibody, with laboratory evidence linking donor CD99 expression to red cell phagocytosis.

PMID41937461
JournalTransfusion
Publication Date2026-04-05
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Case report of a 74-year-old woman (with a history of Parkinson's disease) who experienced an acute hemolytic transfusion reaction caused by anti‑CD99 alloantibody, with laboratory evidence linking donor CD99 expression to red cell phagocytosis.

WHY IT MATTERS

Research significance

This has minimal direct value for Parkinson's therapeutic discovery but is clinically relevant for transfusion safety in PD patients and highlights a rare immune complication rather than informing PD mechanisms or drug targets.

ABSTRACT

Source abstract

BACKGROUND: Anti-CD99 is a rare alloantibody with unclear clinical significance in transfusion medicine. We report a case of acute hemolytic transfusion reaction associated with anti-CD99 in a female patient. CASE REPORT: The patient was a 74-year-old woman originally from Kyushu Prefecture with a history of pregnancy and transfusions. The patient was also diagnosed with Parkinson's disease 13 years ago and recently hospitalized with intestinal obstruction and aspiration pneumonia. During hospitalization, she developed anemia requiring red blood cell transfusions; pre-transfusion antibody screening before the second transfusion revealed pan-reactivity with all panel cells. Antibody identification testing at the Japanese Red Cross Kyushu Block Blood Center detected anti-CD99 in the patient's serum. As CD99-negative blood was unavailable, two units of randomly selected red blood cells derived from male donors were transfused. Shortly after the second transfusion, the patient developed chills, fever, hematuria, and laboratory evidence of hemolysis. Flow cytometry and monocyte phagocytosis assays demonstrated that CD99 expression on donor red blood cells correlated with susceptibility to phagocytosis. The patient subsequently died on day 12 after the second transfusion due to worsening pneumonia. CONCLUSION: Antibody-producing CD99-negative individuals are extremely rare; in Japan, only 10 cases have been identified since 1993 at Japanese Red Cross blood centers. All of these patients were women from the Kyushu region. The present case demonstrates the potential of anti-CD99 to cause acute hemolytic transfusion reactions and represents a valuable clinical report, emphasizing the importance of careful transfusion management in patients with anti-CD99.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic